Skip to main content

Lupus (Systemic Lupus Erythematosus) and cannabis in North Dakota

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
Up to 3 oz of usable ca…
POSSESSION
$50/yr
STATE FEE
14–45 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

North Dakota statute and program

The North Dakota Medical Marijuana Program is the operating authority for North Dakota patient certification. The authoritative legal text is: North Dakota Century Code Chapter 19-24.1: Medical Marijuana. The program portal is at North Dakota Medical Marijuana Program.

What the evidence says about cannabis and Lupus (Systemic Lupus Erythematosus)

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease in which the immune system produces autoantibodies that attack the body's own tissues. Inflammation can affect joints, skin, kidneys, blood, lungs, heart, and the nervous system. Lupus is a relapsing-remitting disease — patients experience flares and periods of relative quiescence.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Lupus (Systemic Lupus Erythematosus) page.

How to qualify in North Dakota

The North Dakota Medical Marijuana Program requires the following registration steps for a Lupus (Systemic Lupus Erythematosus) patient (or any qualifying diagnosis):

  1. Get a written certification from a North Dakota-licensed healthcare provider. Under N.D.C.C. Ch. 19-24.1 (Compassionate Care Act, Measure 5 of 2016 as amended), any North Dakota-licensed physician, advanced practice registered nurse, or physician assistant may certify a patient for one of the enumerated debilitating medical conditions: cancer, HIV/AIDS, hepatitis C, ALS, PTSD, severe debilitating pain, intractable nausea, severe muscle spasms, glaucoma, Crohn’s, MS, autism spectrum, Tourette’s, ulcerative colitis, severe debilitating chronic pain, terminal illness, neuropathy, and others under §19-24.1-01.
  2. Apply through the North Dakota Medical Marijuana Program portal. The patient creates an account in the North Dakota Health and Human Services (HHS) Medical Marijuana Program portal, uploads the healthcare provider written certification, a North Dakota driver license or state ID, a passport-style photograph, and proof of North Dakota residency.
  3. Pay the $50 state registration fee. The two-year North Dakota medical marijuana patient ID card fee is $50 (no reduced fee tier as of current HHS rules). Caregiver registration is $50 with a separate state and federal background check. Fees are paid online during HHS portal submission.
  4. Receive the card and purchase from a North Dakota dispensary. North Dakota medical marijuana patient ID cards are issued within roughly 30 days of complete application. With the card, patients may purchase up to 2.5 ounces every 30 days from any of the licensed North Dakota medical marijuana dispensaries. Approved forms include flower, capsules, tinctures, topicals, and concentrates. North Dakota does not honor out-of-state medical cards. Cards renew at the two-year mark with fresh practitioner certification.
State registration fee
$50
Physician visit (typical)
$150–$300
Certification to card
14–45 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full North Dakota registration steps, fees, and reciprocity rules, see the North Dakota cannabis-laws page.

ICD-10 code

A certifying physician documenting Lupus (Systemic Lupus Erythematosus) for the North Dakota medical cannabis program will typically record ICD-10 M32.9 or SNOMED-CT 55464009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does North Dakota list Lupus (Systemic Lupus Erythematosus) as a qualifying condition for medical cannabis?

No. North Dakota's qualifying-condition list does not currently include Lupus (Systemic Lupus Erythematosus), and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Lupus (Systemic Lupus Erythematosus) in North Dakota have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. North Dakota program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a North Dakota medical marijuana card for Lupus (Systemic Lupus Erythematosus)?

Because North Dakota does not currently list Lupus (Systemic Lupus Erythematosus) as a qualifying condition, a card for Lupus (Systemic Lupus Erythematosus) alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in North Dakota who is registered with North Dakota Medical Marijuana Program and willing to evaluate Lupus (Systemic Lupus Erythematosus) cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. North Dakota does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. The authoritative source for the current process is the North Dakota Medical Marijuana Program site at https://www.hhs.nd.gov/medical-marijuana; the state updates fees, forms, and physician registration rules periodically.

What does the evidence say about cannabis for Lupus (Systemic Lupus Erythematosus)?

For Lupus (Systemic Lupus Erythematosus), evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Lupus (Systemic Lupus Erythematosus) lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Lupus (Systemic Lupus Erythematosus) should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Lupus (Systemic Lupus Erythematosus) and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Lupus (Systemic Lupus Erythematosus); the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. North Dakota Century Code Chapter 19-24.1: Medical Marijuanaaccessed May 16, 2026
  2. North Dakota Century Code §19-03.1-23.1: Decriminalization of Possession of Small Amountsaccessed May 16, 2026
  3. North Dakota Department of Health and Human Services: Medical Marijuana Programaccessed May 16, 2026
  4. Wikipedia: Cannabis in North Dakotaaccessed May 16, 2026
  5. NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases: Lupusaccessed May 18, 2026
  6. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026

    “Substantial evidence that cannabis or cannabinoids are effective for chronic pain in adults.”

  7. Lupus Foundation of America: Marijuana and Lupusaccessed May 18, 2026
  8. American College of Rheumatology: 2023 Guideline for SLE Management (executive summary)accessed May 18, 2026
  9. MedlinePlus: Systemic lupus erythematosusaccessed May 18, 2026